Bevacizumab in age-related macular degeneration – comparison of subjective estimation of vision with objective test results
More details
Hide details
Department of Ophthalmology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
Private Ophthalmologic Surgery, Katowice, Poland
Clinical Department of Laryngology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
Corresponding author
Agnieszka Piotrowska-Seweryn
Clinical Department of Laryngology, School of Medicine in Katowice, Medical University of Silesia, ul. Francuska 20-24, 40-027 Katowice, tel. +48 696 729 897, e-mail:
Ann. Acad. Med. Siles. 2015;69:33-41
Anti-VEGF therapy plays a great role in medicine, especially in opthalmology. The aim of the therapy is to inhibit the VEGF-A factors that are responsible for the angiogenesis in diseases such as the wet form of age-related macular degeneration (AMD). One of the monoclonal anti-VEGF antibodies is bevacizumab (Avastin®; Genentech, Inc., South San Francisco, CA). The aim of the study was to compare the subjective estimation of visual acuity with objective test results in patients undergoing anti-VEGF therapy using Avastin.

Materials and methods:
The authors report a study of 57 patients (37 females and 20 males) with exudative AMD whose near and distance visual acuity was examined before the first dose of Avastin and 1 month after the third injection. Additionally, an original questionnaire evaluating the subjective state of vision during the activities of daily routine was performed.

When examining distance visual acuity, 29 patients made an improvement, deterioration was reported in 5 cases and in 23 cases the results remained unaltered. The results were correlated with the subjective estimation.

1. Avastin stabilizes the degeneration process of AMD in most patients and sometimes improves visual acuity. 2. There is a positive correlation between the objective test results and subjective opinion in patients undergoing anti-VEGF therapy using Avastin.

Stachura J., Domagała W. Patologia znaczy słowo o chorobie. Tom I, PAU. Kraków 2008; 479.
Banyś A., Bułaś L., Długosz E., Szulc-Musiał B., Jankowski A. Angiogeneza w chorobie nowotworowej. Farm. Pol. 2009; 65: 247–250.
Lynch S.S., Cheng C.M. Bevacizumab for neovascular ocular diseases. Ann. Pharmacother. 2007; 41: 614–625.
Van Meter M.E., Kim E.S. Bevacizumab: current updates in treatment. Curr. Opin. Oncol. 2010; 22: 586–591.
Strickler J.H., Hurwitz H.I. Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer. Oncologist 2012; 17: 513–524.
Stevenson C.E., Nagahashi M., Ramachandran S., Yamada A., Bear H.D., Takabe K. Bevacizumab and breast cancer: what does the future hold? Future Oncol. 2012; 8: 403–414.
Su Y., Yang W.B., Li S., Ye Z.J., Shi H.Z., Zhou Q. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 2012; 7: e35629.
Kim Y.C., Kim S.D., Kim K.S. A case of idiopathic central serous chorioretinopathy in a 12-year-old male treated with bevacizumab. Korean J. Ophthalmol. 2012; 26: 391–393.
Aydin E. The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy. J. Ocul. Pharmacol. Ther. 2013; 29: 10–13.
Jamil A.Z., Rahman F.U., Iqbal K., Ansari H.M., Iqbal W., Mirza K.A. Intravitreal bevacizumab in central serous chorioretinopathy. J. Coll. Physicians. Surg. Pak. 2012; 22: 363–366.
Cintra L.P., Costa R.A., Ribeiro J.A., Calucci D., Scott I.U., Messias A., Jorge R. Intrvitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE STUDY): 1-Year Results. Retina. 2013; 33: 1109–1116.
Niżankowska M.H. Podstawy Okulistyki. Podręcznik dla lekarzy i studentów medycyny. Volumed, Wyd. II, Wrocław 2000; 291–294.
Junghans A., Sies H., Stahl W. Macular pigments lutein and zeaxanthin as blue light filters studied in liposomes. Arch. Biochem. Biophys. 2001; 391: 160–164.
Sommerburg O.G., Siems W.G., Hurst J.S., Lewis J.W., Kliger D.S., van Kuijk F.J. Lutein and Zeaxanthin are associated with photoreceptors in the human retina. Current Eye Research. 1999; 19: 491–495.
Landrum J.T., Bone R.A., Moore L.L., Gomez C.M. Analysis of Zeaxanthin distribution within individual humans retinas. Methods Enzymol. 1999; 299: 457–467.
Polaczek-Krupa B., Czechowicz-Janicka K. Objawy, diagnostyka i leczenie zwyrodnienia plamki związanego z wiekiem. Przew. Lek. 2005; 8: 45–53.
Mierzejewski A. Rola angiografii fluoresceinowej w diagnostyce starczego zwyrodnienia plamki. Okulistyka 2002; 2: 25–34.
Kański J.J. Okulistyka kliniczna. II wydanie polskie, Górnicki Wydawnictwo Medyczne, Wrocław 2005; 417.
Bird A.C., Bressler N.M., Bressler S.B. et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv. Ophthalmol.1995; 39: 367–374.
Regillo C.D., Brown D.M., Abraham P. et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am. J. Ophthalmol. 2008; 145: 239–248.
Heimes B., Lommatzsch A., Zeimer M., Gutfleisch M., Spital G., Dietzel M., Pauleikhoff D. Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefes Arch. Clin. Exp. Ophthalmol. 2011; 249: 639–644.
Algvere P.V., Steen B., Seregard S., Kvanta A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol. 2008; 86: 482–489.
Stewart M.W. Predicted biologic activity of intravitreal bevacizumab. Retina 2007; 27: 1196–1200.
Sampat K.M., Garg S.J. Complications of intravitreal injections. Curr. Opin. Ophthalmol. 2010; 21: 178–183.
Flaxel C., Schain M.B., Hamon S.C., Francis P.J. Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study. Retina 2012; 32: 417–423.
Gomi F., Sawa M., Tsujikawa M., Nishida K. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina 2012; 32: 1804–1810.
Zweifel S.A., Engelbert M., Khan S., Freund K.B. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. Retina 2009; 29: 1527–1531.
Wyględowska-Promieńska D., Piotrowska-Gwóźdź A., Piotrowska-Seweryn A., Mazur-Piotrowska G., Rokicki W. Combination of bevacizumab and bromfenac therapy in age-related macular degeneration: A pilot study. Med. Sci. Monit. 2014; 20: 1–7 DOI: 10.12659/MSM.890 671.
Journals System - logo
Scroll to top